decline and loss of independence. 3 , 4 Moreover, hospitalization is associated with increased healthcare expenses and a significant financial burden for older adults with cancer and their families. 5 – 7 Identification of validated risk factors for
Search Results
External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy
Mostafa R. Mohamed, Kah Poh Loh, Supriya G. Mohile, Michael Sohn, Tracy Webb, Megan Wells, Sule Yilmaz, Rachael Tylock, Eva Culakova, Allison Magnuson, Can-Lan Sun, James Bearden, Judith O. Hopkins, Bryan A. Faller, and Heidi D. Klepin
Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010
Mikkael A. Sekeres
be an overestimate, a rate of 60,000 people likely underestimates the impact of the disease. Risk Factors for Developing MDS The greatest risk factor for developing MDS is advanced age, with yearly incidence rates increasing 10-fold for
Factors Associated With False-Positive Recalls in Mammography Screening
Xinhe Mao, Wei He, Keith Humphreys, Mikael Eriksson, Natalie Holowko, Fredrik Strand, Per Hall, and Kamila Czene
between breast cancer risk factors and false-positive recalls may help reduce their occurrence. Previous studies have found that high breast density is associated with false-positive recalls. 11 – 13 However, no study thus far has investigated the
Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents
Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek
-institution retrospective study, we sought to identify the prevalence of hypocalcemia and determine the risk factors for development of hypocalcemia in a diverse, multiracial population of patients with cancer receiving treatment with BMAs. Patients and Methods We performed
Risk Assessment and Prophylaxis for VTE in Cancer Patients
Alok A. Khorana
.medscape.org/journal/jnccn ; (4) view/print certificate. Release date: July 5, 2011; Expiration date: July 5, 2012 Learning Objectives Upon completion of this activity, participants will be able to: Describe clinical risk factors for VTE in cancer, based on a review Describe
Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma
Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo
risk factors for death and hospitalization during the first month of rituximab-based immunochemotherapy using population-based data from Medicare beneficiaries. Patients and Methods Data Source and Cohort Selection This study used
Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen
update of the NCCN Guidelines are available at NCCN.org. VTE Risk Assessment in Patients With Cancer VTE risk factors in patients with cancer can be grouped into 3 general categories: patient-related factors, cancer-related factors, and treatment
Identification of Risk Factors for Chemotherapy-Related 30-Day Readmissions
Jeremy Lund, Angela Pearson, and Georgia Keriazes
call for a multidisciplinary, coordinated effort to identify potential risk factors for readmission. 2 With the recent changes to repayment structures by CMS for selected diagnoses and the prospect of that list growing, it is imperative for
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response
Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang
the risk factors for chronic IMDC or its effects on the overall cancer outcome. We attempted to bridge this knowledge gap in a retrospective study of patients with advanced malignancies at The University of Texas MD Anderson Cancer Center (MDACC
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen
summarized and compared between those with and without SREs using the Fisher exact test for the categorical risk factors and the Kruskal-Wallis test for the continuous variables. All statistical analyses were performed using SAS, version 9.4 (SAS Institute